NCT07470489
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07470489
Title A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial
Acronym ZEPHYR
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA